Indefinite Delivery Contract SPE2DR25D9151

The federal contract IDV award SPE2DR25D9151 was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of pharmaceutical products and medical supplies to support the Department of Defense (DoD) and other federal agencies. This single-award Indefinite Delivery Contract (IDC), valued at up to $4,999,999, covers a wide range of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, including specialized products such as Xolair, Trikafta, Keytruda, Botox, and Nucala. The contract has an ultimate completion date of December 31, 2036 and was awarded on August 1, 2025.

The original solicitation, identified as the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), aims to establish multiple prime vendor contracts for worldwide pharmaceutical support to the Defense Health Agency, DoD customers, the U.S. Coast Guard, and other designated providers. The solicitation, expected to be issued in March 2024, will cover a 30-month base period with three 30-month option periods, for a total estimated value of $30.3 billion. The contract will be awarded on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet lines of effort. The procurement will be conducted as a Lowest Price Technically Acceptable (LPTA) acquisition, with distribution fees as the primary evaluation factor.